Shares in CSL Limited (ASX: CSL) have plummeted this week, despite no news having been released by the company.
At the time of writing, the CSL share price is $282.68. That represents a fall of 7.48% since Monday’s open for the largest of all ASX-listed companies. That figure includes today’s 1.37% drop.
The ongoing fall seems to have been spurred by a broker note released by Citi on Wednesday. The broker downgraded the company’s shares to a neutral rating and retained its $310 price target.
Let’s look at the note that’s seemingly driven the the biotech company’s share price down this week.
Citi downgrades CSL
The CSL share price looks to have faltered after Citi suggested the plasma collection market recovery is fully priced in.
Citi moved its recommendation for CSL shares from buy to neutral as the company’s share price has outperformed since March and it expects the plasma collection market to normalise this year.
Citi said its rating change is “purely valuation based”.
However, the broker stated it’s still 15% ahead of the consensus for 2023 financial year estimations.
The broker also noted it sees some upside risk to do with the CSL112 phase III trial currently being undertaken by the company.
The clinical trial is working to confirm the efficacy and safety of CSL112 in reducing reoccurring cardiovascular events after an acute myocardial infarction (MI). Myocardial infarction is the medical name for a heart attack.
CSL112 has so far shown an ability to remove cholesterol from arteries.
The trial is aiming to enrol more than 17,000 patients from approximately 1,000 medical centres globally. Its results are due at the end of this year.
CSL share price snapshot
This year has been tough on the CSL share price, which has fallen 0.81% year to date.
Shares in CSL are also 3.88% lower than they were this time last year.
The company has a market capitalisation of around $130 billion, with approximately 455 million shares outstanding.
The post The CSL (ASX:CSL) share price has fallen 7% this week appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL Limited right now?
Before you consider CSL Limited , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL Limited wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
More reading
- ASX 200 up 0.3%: CSL downgraded, Zip drops, Charter Hall impresses
- CSL (ASX:CSL) share price falls on broker downgrade
- 3 top ASX shares in sector selling at 30% discount: expert
- 2 blue chip ASX shares rated as buys
- ASX 200 Weekly Wrap: ASX makes it 5 out of 5
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/2T2UfqV
Leave a Reply